On February 14, 2019, the PTAB issued final written decisions in two separate IPRs filed by Sanofi-Aventis, Genzyme Corp., and Regeneron...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
IPR
-
-
The PTAB recently denied institution of two IPRs filed by CSL Behring LLC, CSL Behring GMBH, and CSL Behring Recombinant Facility AG...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
We previously wrote about Genentech’s U.S. Patent No. 6,407,213 (“the ’213 patent”) to Carter, first in October 2017, and more...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported, one of three Pfizer IPR petitions filed in April 2017 against Biogen-owned patents claiming methods of treatment...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The August 2018 Update to the PTAB Trial Practice Guide added guidance regarding the Patent Trial and Appeal Board’s (“the Board”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Recently, Pfizer was denied institution of two follow-on inter partes review (IPR) petitions, IPR Nos. 2018-00330 and 2018-00331 (“the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On August 10, 2018, AbbVie, Inc. and AbbVie Biotechnology Ltd. (collectively “AbbVie”) sued Sandoz Inc., Sandoz GMBH, and Sandoz...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The PTAB recently instituted a second IPR of US Patent 9,296,821 (“the ’821 patent”), which covers certain uses of Rituxan®...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]